×
IBio EBIT 2010-2024 | IBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
IBio ebit from 2010 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
IBio EBIT 2010-2024 | IBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
IBio ebit from 2010 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$159.1B
Vertex Pharmaceuticals (VRTX)
$124.6B
Bristol Myers Squibb (BMY)
$118.6B
Gilead Sciences (GILD)
$114.8B
CSL (CSLLY)
$88.8B
Regeneron Pharmaceuticals (REGN)
$86B
GSK (GSK)
$71.3B
Argenex SE (ARGX)
$35.6B
Alnylam Pharmaceuticals (ALNY)
$33.3B
BioNTech SE (BNTX)
$24.8B
Biogen (BIIB)
$24B
Illumina (ILMN)
$22.6B
BeiGene (BGNE)
$18.8B
Moderna (MRNA)
$15.3B
Incyte (INCY)
$15B
Genmab (GMAB)
$14B
Insmed (INSM)
$12.7B
BioMarin Pharmaceutical (BMRN)
$12.5B
Vaxcyte (PCVX)
$11.6B
Bio-Techne Corp (TECH)
$11.5B
Sarepta Therapeutics (SRPT)
$10.4B
Exelixis (EXEL)
$10B
Revolution Medicines (RVMD)
$9.7B
QIAGEN (QGEN)
$9.6B
Exact Sciences (EXAS)
$9.4B
Bio-Rad Laboratories (BIO.B)
$9.4B
Intra-Cellular Therapies (ITCI)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Repligen (RGEN)
$8B
Ascendis Pharma (ASND)
$7.5B